Mr. Will Rascan reports

NOVA MENTIS ANNOUNCES CHANGE OF DIRECTORS AND OFFICERS

Nova Mentis Life Science Corp. has appointed Dr. Georg Hochwimmer to the company's board of directors, effective Dec. 29, 2023.

Dr. Hochwimmer is chief analyst at General Research GmbH, a leading Munich-based securities research and analysis firm. Dr. Hochwimmer is a noted business consultant and academic responsible for aiding in the development of several highly profitable companies throughout Europe. He serves as the chief executive officer of supraMAT Technologies AG, which is a business incubator for German technology companies. He founded leading German technical start-ups, such as NGP Polymers, SmartDyelivery and Trophosys. He is also a managing director of Microdrop Technologies, which is a globally leading 3-D microprinting company. Dr. Hochwimmer has earned advanced degrees in chemistry and mechanical engineering.

The company further announces the resignation of Jacqueline McConnell as chief operating officer and director of the company, effective Dec. 29, 2023. Ms. McConnell will continue on with Nova Mentis as a consultant, assisting the company in its clinical trial and other potential opportunities.

The board would like to thank Ms. McConnell for her involvement with Nova Mentis and wishes her the best in future endeavours.

About Nova Mentis Life Science Corp.

Nova Mentis is a Canadian-based biotechnology company and global leader in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. Nova Mentis is the first biotech company to achieve orphan drug designation in both the United States and European Union for the use of psilocybin in the treatment of fragile X syndrome.

Nova Mentis's goal is to diagnose and treat debilitating chronic conditions that have unmet medical needs, such as autism spectrum disorder and FXS.

We seek Safe Harbor.